- Previous Close
6.55 - Open
6.43 - Bid 4.51 x 200
- Ask 8.21 x 100
- Day's Range
6.34 - 6.43 - 52 Week Range
2.77 - 7.89 - Volume
3,460 - Avg. Volume
40,331 - Market Cap (intraday)
25.141M - Beta (5Y Monthly) 2.19
- PE Ratio (TTM)
-- - EPS (TTM)
-1.15 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.20
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
www.tenaxthera.comRecent News: TENX
View MorePerformance Overview: TENX
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TENX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TENX
View MoreValuation Measures
Market Cap
24.74M
Enterprise Value
15.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.48%
Return on Equity (ttm)
-35.17%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.6M
Diluted EPS (ttm)
-1.15
Balance Sheet and Cash Flow
Total Cash (mrq)
94.85M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.41M